Coste-efectividad del Rivaroxabán frente a Dalteparina para prevención de trombosis recurrente en el paciente con cáncer
Introducción: En Colombia, el 90,9% de los pacientes con cáncer y eventos trombóticos se manejan con heparinas de bajo peso molecular, el 9,1% de los pacientes tiene irregular o mala adherencia. Rivaroxabán, un nuevo anticoagulante oral ha mostrado menor recurrencia de trombosis venosa y mejor adher...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2019
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- spa
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/20367
- Acceso en línea:
- https://doi.org/10.48713/10336_20367
https://repository.urosario.edu.co/handle/10336/20367
- Palabra clave:
- Rivaroxabán
Dalteparina
Cáncer
Tromboembolismo
Farmacoeconomía
Ciencias médicas, Medicina
Rivaroxabán
Dalteparin
Cancer
Thromboembolism
Pharmacoeconomics
Medicina
Epidemiología
- Rights
- License
- Atribución-NoComercial-SinDerivadas 2.5 Colombia
| id |
EDOCUR2_7e836f0e3fd31da9ecf0cfb90d17fc86 |
|---|---|
| oai_identifier_str |
oai:repository.urosario.edu.co:10336/20367 |
| network_acronym_str |
EDOCUR2 |
| network_name_str |
Repositorio EdocUR - U. Rosario |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Coste-efectividad del Rivaroxabán frente a Dalteparina para prevención de trombosis recurrente en el paciente con cáncer |
| title |
Coste-efectividad del Rivaroxabán frente a Dalteparina para prevención de trombosis recurrente en el paciente con cáncer |
| spellingShingle |
Coste-efectividad del Rivaroxabán frente a Dalteparina para prevención de trombosis recurrente en el paciente con cáncer Rivaroxabán Dalteparina Cáncer Tromboembolismo Farmacoeconomía Ciencias médicas, Medicina Rivaroxabán Dalteparin Cancer Thromboembolism Pharmacoeconomics Medicina Epidemiología |
| title_short |
Coste-efectividad del Rivaroxabán frente a Dalteparina para prevención de trombosis recurrente en el paciente con cáncer |
| title_full |
Coste-efectividad del Rivaroxabán frente a Dalteparina para prevención de trombosis recurrente en el paciente con cáncer |
| title_fullStr |
Coste-efectividad del Rivaroxabán frente a Dalteparina para prevención de trombosis recurrente en el paciente con cáncer |
| title_full_unstemmed |
Coste-efectividad del Rivaroxabán frente a Dalteparina para prevención de trombosis recurrente en el paciente con cáncer |
| title_sort |
Coste-efectividad del Rivaroxabán frente a Dalteparina para prevención de trombosis recurrente en el paciente con cáncer |
| dc.contributor.advisor.none.fl_str_mv |
Martínez del Valle, Anacaona |
| dc.subject.spa.fl_str_mv |
Rivaroxabán Dalteparina Cáncer Tromboembolismo Farmacoeconomía |
| topic |
Rivaroxabán Dalteparina Cáncer Tromboembolismo Farmacoeconomía Ciencias médicas, Medicina Rivaroxabán Dalteparin Cancer Thromboembolism Pharmacoeconomics Medicina Epidemiología |
| dc.subject.ddc.spa.fl_str_mv |
Ciencias médicas, Medicina |
| dc.subject.keyword.spa.fl_str_mv |
Rivaroxabán Dalteparin Cancer Thromboembolism Pharmacoeconomics |
| dc.subject.lemb.spa.fl_str_mv |
Medicina Epidemiología |
| description |
Introducción: En Colombia, el 90,9% de los pacientes con cáncer y eventos trombóticos se manejan con heparinas de bajo peso molecular, el 9,1% de los pacientes tiene irregular o mala adherencia. Rivaroxabán, un nuevo anticoagulante oral ha mostrado menor recurrencia de trombosis venosa y mejor adherencia en ensayos clínicos controlados en pacientes con cáncer, sin embargo, los pacientes tratados con Rivaroxabán han presentado mayor riesgo de sangrado. Objetivo: Realizar un análisis de coste-efectividad sobre el uso de rivaroxabán frente a dalteparina para la prevención de trombosis recurrente en pacientes con cáncer. Materiales y métodos: El análisis de coste-efectividad se ha diseñado mediante un modelo farmacoeconómico, tomando como unidad de efectividad cada año de vida ganado por el tratamiento con rivaroxabán o dalteparina. La probabilidad de que aparezcan los desenlaces de interés se ha tomado de un ensayo clínico controlado que evalúa eficacia y seguridad de las dos intervenciones. Los costes valorados incluyen: el diagnóstico y tratamiento de los eventos de efectividad y seguridad. No se contemplan otros costos. La perspectiva del estudio es la del Sistema General de Seguridad Social Integral Colombiano y el horizonte temporal elegido para el análisis es 6 meses. Resultados: Se analizó una cohorte hipotética de 10.000 pacientes en cada intervención. No hubo diferencia entre las intervenciones en los años de vida ganados (10,8 años de vida ganados). La cohorte de pacientes con Rivaroxabán presentó menos eventos trombóticos (3,94 vs 8,86%) y más episodios de sangrado (sangrado mayor 5,42% vs 2,95% y sangrado menor 12,3% vs 3,45%) El costo de 6 meses de tratamiento en la cohorte con Rivaroxabán es de COP 40.844’290.368 y el de Dalteparina es de COP 59.252’261.591. El análisis de sensibilidad evidenció que a pesar de un aumento del 10% en el costo de rivaroxabán y una disminución del 10% del costo de la dalteparina, rivaroxabán sigue siendo la opción más costoefectiva. Restringir el rivaroxabán en pacientes con neoplasia gastroesofágica incrementa la diferencia de costos en un 62% a favor del tratamiento oral. Conclusiones: Rivaroxabán puede ser considerado una opción costo-efectiva para el tratamiento del tromboembolismo venoso en pacientes con cáncer ya que reduce costos cuando se compara con dalteparina. La seguridad del rivaroxabán aumenta con el uso discrecional en pacientes con patología urinaria y exclusión del paciente con cáncer esofágico y gastroesofágico. |
| publishDate |
2019 |
| dc.date.accessioned.none.fl_str_mv |
2019-09-30T18:52:20Z |
| dc.date.available.none.fl_str_mv |
2019-09-30T18:52:20Z |
| dc.date.created.none.fl_str_mv |
2019-09-19 |
| dc.type.eng.fl_str_mv |
bachelorThesis |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_7a1f |
| dc.type.document.spa.fl_str_mv |
Trabajo de grado |
| dc.type.spa.spa.fl_str_mv |
Trabajo de grado |
| dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.48713/10336_20367 |
| dc.identifier.uri.none.fl_str_mv |
https://repository.urosario.edu.co/handle/10336/20367 |
| url |
https://doi.org/10.48713/10336_20367 https://repository.urosario.edu.co/handle/10336/20367 |
| dc.language.iso.spa.fl_str_mv |
spa |
| language |
spa |
| dc.rights.spa.fl_str_mv |
Atribución-NoComercial-SinDerivadas 2.5 Colombia |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.acceso.spa.fl_str_mv |
Abierto (Texto Completo) |
| dc.rights.uri.none.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ |
| rights_invalid_str_mv |
Atribución-NoComercial-SinDerivadas 2.5 Colombia Abierto (Texto Completo) http://creativecommons.org/licenses/by-nc-nd/2.5/co/ http://purl.org/coar/access_right/c_abf2 |
| dc.format.mimetype.none.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
Universidad del Rosario |
| dc.publisher.department.spa.fl_str_mv |
Facultad de medicina |
| institution |
Universidad del Rosario |
| dc.source.bibliographicCitation.spa.fl_str_mv |
Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP. Anticoagulation strategies in patients with cancer: JACC review topic of the week. J Am Coll Cardiol. 2019;73(11):1336–49 Karimi M, Cohan N. Cancer-associated thrombosis. Open Cardiovasc Med J. 2010;4:78–82 Khorana A, Francis C, Culakova E, Kuderer N, Lyman G. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost [Internet]. 2007;5:632–4. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L46680709%0Ahttp://dx.doi.org/10.1111/j.1538-7836.2007.02374.x%0Ahttp://sfx.library.uu.nl/utrecht?sid=EMBASE&issn=15387933&id=doi:10.1111%2Fj.1538-7836.2007.02374.x&atitle=Thromboemb Puurunen MK, Gona PN, Larson MG, Murabito JM, Magnani JW, O’Donnell CJ. Epidemiology of venous thromboembolism in the Framingham Heart Study. Thromb Res [Internet]. 2016;145:27–33. Available from: http://dx.doi.org/10.1016/j.thromres.2016.06.033 Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood [Internet]. 2002;100(10):3484–8. Available from: https://www.mendeley.com/catalog/identification-specific-inhibitor-histone-methyltransferase-suvar39-2/ Es N van, Blekera SM, Nisio M Di. Cancer-associated unsuspected pulmonary embolism. Thromb Res [Internet]. 2014;133:S172–8. Available from: http://dx.doi.org/10.1016/S0049-3848(14)50028-X Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-Molecular-Weight Heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–53 Streiff M, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, et al. Cancer-associated venous thromboembolic disease - NCCN guidelines version 1.2019. 2019 Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy and prevention of thrombosis , 9th ed : American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):e419S-e494S Cristina M, Giustozzi M, Bonitta G, Agnelli G, Becattini C. Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer : A network meta-analysis. Thromb Res. 2018;170:175–80 Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–23 Khorana AA, Dalal MR, Lin J, Connolly GC. Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clin Outcomes Res. 2013;5:101–8 Dennis R. Estudio nacional sobre tromboembolismo venoso en población hospitalaria en Colombia. Acta Med … [Internet]. 1996;21:55–63. Available from: http://actamedicacolombiana.com/anexo/articulos/02-1996-02-Estudio_nacional_sobre_tromboembolismo_venoso_en.pdf Denis RJ, Rojas MX, Molina Á, Roa J, Granados M, Londoño A, et al. Curso clínico y supervivencia en embolia pulmonar. Resultados del registro multicéntrico colombiano (EMEPCO). Acta médica Colomb. 2008;33(3):111–6 Perilla O. Caracterización clínica de pacientes con enfermedad tromboembólica asociada a cáncer en el Instituto Nacional de Cancerología. 2018 Verso M, Franco L, Giustozzi M, Becattini C, Agnelli G. Treatment of venous thromboembolism in patients with cancer: what news from clinical trials? Thromb Res. 2018;164:S168–71 Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer [Internet]. 2010;102(S1):S2–9. Available from: http://dx.doi.org/10.1038/sj.bjc.6605599 Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease - CHEST guideline and expert panel report. Chest. 2016;149(2):315–52 Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654–7 Khorana AA, Yannicelli D, McCrae KR, Milentijevic D, Crivera C, Nelson WW, et al. Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed? Thromb Res. 2016;145:51–3 Siwan S, Nelson A, Noble S. Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study. Patient Prefer Adherence. 2014;8:453–61 Ross JA, Miller MM, Rojas Hernandez C. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: a retrospective analysis. Thromb Res. 2017;150:86–9 Moreno M, Mejía A, Héctor C. Manual para la elaboración de evaluaciones económicas en salud. Instituto de Evaluación Tecnológica en Salud – IETS. 2014. 1–33 p Deng A, Galanis T, Graham MG. Venous thromboembolism in cancer patients. Hosp Pract (1995). 2014;42(5):24–33 Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–22 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med. 2000;160:809–17 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712–23 Harvey D, Zhou H, Chew HK, Wun T, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458–64 Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer [Internet]. 2013;49:1404–13. Available from: http://dx.doi.org/10.1016/j.ejca.2012.10.021 Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. Plos Med. 2012;9(7):1–19 Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res [Internet]. 2013;131:24–30. Available from: http://dx.doi.org/10.1016/j.thromres.2012.10.007 Cronin-Fenton DP, Søndergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer. 2010;103:947–53 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339–46 Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg [Internet]. 2006;243(1):89–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16371741%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC1449979 Blom JW, Vanderschoot JPM, Oostindiër MJ, Osanto S, Van Der Meer FJM, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4:529–35 Falanga A, Russo L, Milesi V, Vignoli A. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol. 2017;118:79–83 Fernandes CJ, Morinaga LTK, Jr JLA, Castro MA, Calderaro D, Jardim CVP, et al. Cancer-associated thrombosis : the when , how and why. 2019;28:1–11. Available from: http://dx.doi.org/10.1183/16000617.0119-2018 Elyamany G, Alzahrani AM, Bukhary E. Cancer-associated thrombosis: an overview. Clin Med Insights Oncol. 2014;8:129–37 Mukai M, Oka T. Mechanism and management of cancer-associated thrombosis. J Cardiol. 2018;72:89–93 Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RCN. Extrinsic-pathway activation in cancer with high factor Vlla and tissue factor. Lancet. 1995;346:1004–5 Nadir Y, Brenner B. Heparanase procoagulant activity in cancer progression. Thromb Res. 2016;140S1:S44–8 Falanga A, Tartari CJ, Marchetti M. Microparticles in tumor progression. Thromb Res [Internet]. 2012;129(Suppl.1):S132–6. Available from: http://dx.doi.org/10.1016/S0049-3848(12)70033-6 Wun T, White RH. Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk Factors. Cancer Invest. 2009;27(S1):63–74 Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009;27(29):4839–47 Fernandes CJ, Morinaga LTK, Alves JL, Castro MA, Calderaro D, Jardim CVP, et al. Cancer-associated thrombosis: the when, how and why. Eur Respir Rev [Internet]. 2019;28:1–11. Available from: http://dx.doi.org/10.1183/16000617.0119-2018 Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost. 2008;6:601–8 Blom J. W, Osanto S., Rosendaal F. R. The risk of a venous thrombotic event in lung cancer patients : higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost. 2004;2:1760–5 Kroger K, Weiland D, Ose C, Neumann N, Weiss S, Hirsch C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol. 2006;17:297–303 Starling N, Rao S, Cunningham D, Iveson T, Nicolson M, Coxon F, et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum , and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol. 2019;27(23):3786–93 Scappaticci FA, Skillings JR, Holden SN, Gerber H, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and Bevacizumab. J Natl Cancer Inst. 2007;99(16):1232–9 Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab. JAMA. 2008;300(19):2277–85 Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98(10):708–14 Lee AYY, Levine MN, Butler G, Webb C, Costantini L, Gu C, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol. 2006;24(9):1404–8 Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood. 2017;130(13):1499–506 Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007;13(10):2870–6 Sallah S, Husain A, Sigounas V, Wan J, Turturro F, Sigounas G, et al. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res. 2004;10:7238–43 Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients : results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2019;112(7):2703–9 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–8 Ay C, Dunkler D, Marosi C, Chiriac A, Vormittag R, Simanek R, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377–83 Oppelt P, Betbadal A, Nayak L. Approach to chemotherapy-associated thrombosis. Vasc Med. 2015;20(2):153–61 Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy : the Protecht score. Intern Emerg Med. 2012;7:291–2 Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy : a randomised , placebo-controlled , double-blind study. Lancet Oncol [Internet]. 2009;10:943–9. Available from: http://dx.doi.org/10.1016/S1470-2045(09)70232-3 Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601–10 M. DN, E. P, M. C, M. DT, I. R, AWS R. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (Review). Cochrane Libr. 2016;(12):1–164 Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilson PE, Moigne-Amrani AL, et al. Duration of prophylaxis against venous thromboembolism with Enoxaparin after surgery for cancer. N Engl J Med. 2002;346(13):975–81 Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380(8):711–9 Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380(8):720–8 Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2003;349(2):146–53 Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314(7):677–86 Agnelli G, Berkowitz S, Bounameaux H, (Chair) HB, Cohen A, Gallus A, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–510 Mismetti P, Schellong S, Eriksson H, Baanstra D, Sc M, Schnee J, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;36(24):2342–52 Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med [Internet]. 2018;378(7):615–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29231094 Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients : results from the AMPLIFY trial. J Thromb Haemost. 2015;13:2187–91 Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, et al. Treatment of Acute Venous Thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764–72 Agnelli G, Berkowitz S, Bounameaux H, (Chair) HB, Cohen A, Gallus A, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–97 Carrier M, Cameron C, Delluc A, Castellucci L, Khorana AA, Lee AYY. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis : a systematic review and meta-Analysis. Thromb Res [Internet]. 2019;134:1214–9. Available from: http://dx.doi.org/10.1016/j.thromres.2014.09.039 Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline ppdate. J Clin Oncol. 2019 Prins MH, Lensing AWA, Brighton TA, Lyons RM, Rehm J, Trajanovic M, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): A pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014;1(1):e37–46 Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H, et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost. 2015;114(1):150–7 Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE Trial. Am J Med [Internet]. 2017;130:1440–8. Available from: https://doi.org/10.1016/j.amjmed.2017.06.026 Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016;3:e379–87 Li A, Garcia DA, Lyman GH, Carrier M. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res [Internet]. 2019;173:158–63. Available from: https://doi.org/10.1016/j.thromres.2018.02.144 Gobierno Nacional de Colombia. Decreto 2423 del 31 de 2006 - actualizado 2019. 2019 Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. The ISPOR CHEERS Task Force Report. CHEERS Checklist. Items to include when reporting economic evaluations of health interventions. 2019 |
| dc.source.instname.spa.fl_str_mv |
instname:Universidad del Rosario |
| dc.source.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional EdocUR |
| bitstream.url.fl_str_mv |
https://repository.urosario.edu.co/bitstreams/dfd0fa72-bd7b-4cad-b117-3050566ebf62/download https://repository.urosario.edu.co/bitstreams/8170550e-61f4-4c95-a91d-847e24ec0ac9/download https://repository.urosario.edu.co/bitstreams/6d5e9969-bce4-42ff-9585-d3eeafe1187b/download https://repository.urosario.edu.co/bitstreams/2f81d35d-fcda-42b5-a725-6bed33060d05/download https://repository.urosario.edu.co/bitstreams/8d7e89ba-84c2-4ed4-8917-fe22c948de98/download |
| bitstream.checksum.fl_str_mv |
a97fbdbad94f62c7718919777d6b1656 fab9d9ed61d64f6ac005dee3306ae77e 217700a34da79ed616c2feb68d4c5e06 1ea926c602ab41562815469d2169ac97 9083dba89e2f9c3a2db77e491d53ea72 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio institucional EdocUR |
| repository.mail.fl_str_mv |
edocur@urosario.edu.co |
| _version_ |
1814167568647192576 |
| spelling |
Martínez del Valle, Anacaonaa418862e-ed7c-4a1b-a1e3-728e0d592167600Yate Cruz, José AlexanderPuentes Díaz, Andrea LilianaEspecialista en Epidemiología (en Convenio con el CES)Full timee45dace8-6c3a-4bd5-a2d4-25f628580769600ad082a3e-3d5f-449f-a71d-340817a78b696002019-09-30T18:52:20Z2019-09-30T18:52:20Z2019-09-19Introducción: En Colombia, el 90,9% de los pacientes con cáncer y eventos trombóticos se manejan con heparinas de bajo peso molecular, el 9,1% de los pacientes tiene irregular o mala adherencia. Rivaroxabán, un nuevo anticoagulante oral ha mostrado menor recurrencia de trombosis venosa y mejor adherencia en ensayos clínicos controlados en pacientes con cáncer, sin embargo, los pacientes tratados con Rivaroxabán han presentado mayor riesgo de sangrado. Objetivo: Realizar un análisis de coste-efectividad sobre el uso de rivaroxabán frente a dalteparina para la prevención de trombosis recurrente en pacientes con cáncer. Materiales y métodos: El análisis de coste-efectividad se ha diseñado mediante un modelo farmacoeconómico, tomando como unidad de efectividad cada año de vida ganado por el tratamiento con rivaroxabán o dalteparina. La probabilidad de que aparezcan los desenlaces de interés se ha tomado de un ensayo clínico controlado que evalúa eficacia y seguridad de las dos intervenciones. Los costes valorados incluyen: el diagnóstico y tratamiento de los eventos de efectividad y seguridad. No se contemplan otros costos. La perspectiva del estudio es la del Sistema General de Seguridad Social Integral Colombiano y el horizonte temporal elegido para el análisis es 6 meses. Resultados: Se analizó una cohorte hipotética de 10.000 pacientes en cada intervención. No hubo diferencia entre las intervenciones en los años de vida ganados (10,8 años de vida ganados). La cohorte de pacientes con Rivaroxabán presentó menos eventos trombóticos (3,94 vs 8,86%) y más episodios de sangrado (sangrado mayor 5,42% vs 2,95% y sangrado menor 12,3% vs 3,45%) El costo de 6 meses de tratamiento en la cohorte con Rivaroxabán es de COP 40.844’290.368 y el de Dalteparina es de COP 59.252’261.591. El análisis de sensibilidad evidenció que a pesar de un aumento del 10% en el costo de rivaroxabán y una disminución del 10% del costo de la dalteparina, rivaroxabán sigue siendo la opción más costoefectiva. Restringir el rivaroxabán en pacientes con neoplasia gastroesofágica incrementa la diferencia de costos en un 62% a favor del tratamiento oral. Conclusiones: Rivaroxabán puede ser considerado una opción costo-efectiva para el tratamiento del tromboembolismo venoso en pacientes con cáncer ya que reduce costos cuando se compara con dalteparina. La seguridad del rivaroxabán aumenta con el uso discrecional en pacientes con patología urinaria y exclusión del paciente con cáncer esofágico y gastroesofágico.Introduction: In Colombia, 90.9% of patients with cancer and thrombotic events are treated with low molecular weight heparins, 9.1% of patients have irregular or poor treatment adhesion. Rivaroxabán, a new oral anticoagulant, has shown less recurrence of venous thrombosis and better adherence in controlled clinical trials in cancer patients; however, the patients treated with Rivaroxabán have presented a higher risk of bleeding. Objective: To perform a cost-effectiveness analysis about the use of rivaroxabán versus dalteparin for the prevention of recurrent thrombosis in cancer patients. Methods: The cost-effectiveness analysis has been designed using a pharmacoeconomic model, taking each year of life gained by the treatment with rivaroxabán or dalteparin as the unit of effectiveness. The probability that the outcomes of interest appear have been taken from a controlled clinical trial that evaluates the efficacy and safety of both interventions. The assessed costs include: the diagnosis and treatment of the effectiveness and safety events. No other costs are contemplated. The perspective of the study is that of the Social Security General System in Health of Colombia and the time horizon chosen for the analysis is 6 months. Results: A hypothetical cohort of 10,000 patients was analyzed in each intervention. There was no difference between the interventions in the years of life gained (10.8 years of life gained). The cohort of patients with Rivaroxabán had fewer thrombotic events (3.94 vs. 8.86%) and more bleeding episodes (major bleeding 5.42% vs. 2.95% and minor bleeding 12.3% vs. 3.45%) The cost of 6 months of treatment in the cohort with Rivaroxabán is COP 40,844'290,368 and in the cohort with Dalteparina is COP 59,252'261,591. The sensitivity analysis showed that despite a 10% increase in the cost of rivaroxabán and a 10% decrease in the cost of dalteparin, rivaroxabán remains the most cost-effective option. Restricting rivaroxabán in patients with gastroesophageal neoplasia increases the cost difference by 62% in favor of oral treatment. Conclusions: Rivaroxabán can be considered a cost-effective option for the treatment of venous thromboembolism in cancer patients since it reduces costs when compared with dalteparin. The safety of rivaroxabán increases with discretionary use in patients with urinary pathology and exclusion of the patient with esophageal and gastroesophageal cancer.2019-09-30 13:55:01: Script de automatizacion de embargos. "30 sep 2019 El autor selecciona el tipo de acceso restringido, se asigna embargo por dos años. Se le envía correo 30 sep 2019 infrmandole el tiempo de embargo del documento."2021-10-01 01:01:01: Script de automatizacion de embargos. info:eu-repo/date/embargoEnd/2021-09-30application/pdfhttps://doi.org/10.48713/10336_20367 https://repository.urosario.edu.co/handle/10336/20367spaUniversidad del RosarioFacultad de medicinaAtribución-NoComercial-SinDerivadas 2.5 ColombiaAbierto (Texto Completo)EL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.http://creativecommons.org/licenses/by-nc-nd/2.5/co/http://purl.org/coar/access_right/c_abf2Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP. Anticoagulation strategies in patients with cancer: JACC review topic of the week. J Am Coll Cardiol. 2019;73(11):1336–49Karimi M, Cohan N. Cancer-associated thrombosis. Open Cardiovasc Med J. 2010;4:78–82Khorana A, Francis C, Culakova E, Kuderer N, Lyman G. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost [Internet]. 2007;5:632–4. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L46680709%0Ahttp://dx.doi.org/10.1111/j.1538-7836.2007.02374.x%0Ahttp://sfx.library.uu.nl/utrecht?sid=EMBASE&issn=15387933&id=doi:10.1111%2Fj.1538-7836.2007.02374.x&atitle=ThromboembPuurunen MK, Gona PN, Larson MG, Murabito JM, Magnani JW, O’Donnell CJ. Epidemiology of venous thromboembolism in the Framingham Heart Study. Thromb Res [Internet]. 2016;145:27–33. Available from: http://dx.doi.org/10.1016/j.thromres.2016.06.033Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood [Internet]. 2002;100(10):3484–8. Available from: https://www.mendeley.com/catalog/identification-specific-inhibitor-histone-methyltransferase-suvar39-2/Es N van, Blekera SM, Nisio M Di. Cancer-associated unsuspected pulmonary embolism. Thromb Res [Internet]. 2014;133:S172–8. Available from: http://dx.doi.org/10.1016/S0049-3848(14)50028-XLee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-Molecular-Weight Heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–53Streiff M, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, et al. Cancer-associated venous thromboembolic disease - NCCN guidelines version 1.2019. 2019Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy and prevention of thrombosis , 9th ed : American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):e419S-e494SCristina M, Giustozzi M, Bonitta G, Agnelli G, Becattini C. Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer : A network meta-analysis. Thromb Res. 2018;170:175–80Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–23Khorana AA, Dalal MR, Lin J, Connolly GC. Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clin Outcomes Res. 2013;5:101–8Dennis R. Estudio nacional sobre tromboembolismo venoso en población hospitalaria en Colombia. Acta Med … [Internet]. 1996;21:55–63. Available from: http://actamedicacolombiana.com/anexo/articulos/02-1996-02-Estudio_nacional_sobre_tromboembolismo_venoso_en.pdfDenis RJ, Rojas MX, Molina Á, Roa J, Granados M, Londoño A, et al. Curso clínico y supervivencia en embolia pulmonar. Resultados del registro multicéntrico colombiano (EMEPCO). Acta médica Colomb. 2008;33(3):111–6Perilla O. Caracterización clínica de pacientes con enfermedad tromboembólica asociada a cáncer en el Instituto Nacional de Cancerología. 2018Verso M, Franco L, Giustozzi M, Becattini C, Agnelli G. Treatment of venous thromboembolism in patients with cancer: what news from clinical trials? Thromb Res. 2018;164:S168–71Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer [Internet]. 2010;102(S1):S2–9. Available from: http://dx.doi.org/10.1038/sj.bjc.6605599Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease - CHEST guideline and expert panel report. Chest. 2016;149(2):315–52Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654–7Khorana AA, Yannicelli D, McCrae KR, Milentijevic D, Crivera C, Nelson WW, et al. Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed? Thromb Res. 2016;145:51–3Siwan S, Nelson A, Noble S. Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study. Patient Prefer Adherence. 2014;8:453–61Ross JA, Miller MM, Rojas Hernandez C. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: a retrospective analysis. Thromb Res. 2017;150:86–9Moreno M, Mejía A, Héctor C. Manual para la elaboración de evaluaciones económicas en salud. Instituto de Evaluación Tecnológica en Salud – IETS. 2014. 1–33 pDeng A, Galanis T, Graham MG. Venous thromboembolism in cancer patients. Hosp Pract (1995). 2014;42(5):24–33Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–22Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med. 2000;160:809–17Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712–23Harvey D, Zhou H, Chew HK, Wun T, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458–64Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer [Internet]. 2013;49:1404–13. Available from: http://dx.doi.org/10.1016/j.ejca.2012.10.021Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. Plos Med. 2012;9(7):1–19Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res [Internet]. 2013;131:24–30. Available from: http://dx.doi.org/10.1016/j.thromres.2012.10.007Cronin-Fenton DP, Søndergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer. 2010;103:947–53Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339–46Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg [Internet]. 2006;243(1):89–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16371741%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC1449979Blom JW, Vanderschoot JPM, Oostindiër MJ, Osanto S, Van Der Meer FJM, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4:529–35Falanga A, Russo L, Milesi V, Vignoli A. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol. 2017;118:79–83Fernandes CJ, Morinaga LTK, Jr JLA, Castro MA, Calderaro D, Jardim CVP, et al. Cancer-associated thrombosis : the when , how and why. 2019;28:1–11. Available from: http://dx.doi.org/10.1183/16000617.0119-2018Elyamany G, Alzahrani AM, Bukhary E. Cancer-associated thrombosis: an overview. Clin Med Insights Oncol. 2014;8:129–37Mukai M, Oka T. Mechanism and management of cancer-associated thrombosis. J Cardiol. 2018;72:89–93Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RCN. Extrinsic-pathway activation in cancer with high factor Vlla and tissue factor. Lancet. 1995;346:1004–5Nadir Y, Brenner B. Heparanase procoagulant activity in cancer progression. Thromb Res. 2016;140S1:S44–8Falanga A, Tartari CJ, Marchetti M. Microparticles in tumor progression. Thromb Res [Internet]. 2012;129(Suppl.1):S132–6. Available from: http://dx.doi.org/10.1016/S0049-3848(12)70033-6Wun T, White RH. Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk Factors. Cancer Invest. 2009;27(S1):63–74Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009;27(29):4839–47Fernandes CJ, Morinaga LTK, Alves JL, Castro MA, Calderaro D, Jardim CVP, et al. Cancer-associated thrombosis: the when, how and why. Eur Respir Rev [Internet]. 2019;28:1–11. Available from: http://dx.doi.org/10.1183/16000617.0119-2018Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost. 2008;6:601–8Blom J. W, Osanto S., Rosendaal F. R. The risk of a venous thrombotic event in lung cancer patients : higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost. 2004;2:1760–5Kroger K, Weiland D, Ose C, Neumann N, Weiss S, Hirsch C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol. 2006;17:297–303Starling N, Rao S, Cunningham D, Iveson T, Nicolson M, Coxon F, et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum , and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol. 2019;27(23):3786–93Scappaticci FA, Skillings JR, Holden SN, Gerber H, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and Bevacizumab. J Natl Cancer Inst. 2007;99(16):1232–9Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab. JAMA. 2008;300(19):2277–85Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98(10):708–14Lee AYY, Levine MN, Butler G, Webb C, Costantini L, Gu C, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol. 2006;24(9):1404–8Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood. 2017;130(13):1499–506Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007;13(10):2870–6Sallah S, Husain A, Sigounas V, Wan J, Turturro F, Sigounas G, et al. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res. 2004;10:7238–43Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients : results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2019;112(7):2703–9Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–8Ay C, Dunkler D, Marosi C, Chiriac A, Vormittag R, Simanek R, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377–83Oppelt P, Betbadal A, Nayak L. Approach to chemotherapy-associated thrombosis. Vasc Med. 2015;20(2):153–61Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy : the Protecht score. Intern Emerg Med. 2012;7:291–2Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy : a randomised , placebo-controlled , double-blind study. Lancet Oncol [Internet]. 2009;10:943–9. Available from: http://dx.doi.org/10.1016/S1470-2045(09)70232-3Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601–10M. DN, E. P, M. C, M. DT, I. R, AWS R. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (Review). Cochrane Libr. 2016;(12):1–164Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilson PE, Moigne-Amrani AL, et al. Duration of prophylaxis against venous thromboembolism with Enoxaparin after surgery for cancer. N Engl J Med. 2002;346(13):975–81Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380(8):711–9Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380(8):720–8Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2003;349(2):146–53Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314(7):677–86Agnelli G, Berkowitz S, Bounameaux H, (Chair) HB, Cohen A, Gallus A, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–510Mismetti P, Schellong S, Eriksson H, Baanstra D, Sc M, Schnee J, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;36(24):2342–52Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med [Internet]. 2018;378(7):615–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29231094Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients : results from the AMPLIFY trial. J Thromb Haemost. 2015;13:2187–91Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, et al. Treatment of Acute Venous Thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764–72Agnelli G, Berkowitz S, Bounameaux H, (Chair) HB, Cohen A, Gallus A, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–97Carrier M, Cameron C, Delluc A, Castellucci L, Khorana AA, Lee AYY. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis : a systematic review and meta-Analysis. Thromb Res [Internet]. 2019;134:1214–9. Available from: http://dx.doi.org/10.1016/j.thromres.2014.09.039Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline ppdate. J Clin Oncol. 2019Prins MH, Lensing AWA, Brighton TA, Lyons RM, Rehm J, Trajanovic M, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): A pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014;1(1):e37–46Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H, et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost. 2015;114(1):150–7Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE Trial. Am J Med [Internet]. 2017;130:1440–8. Available from: https://doi.org/10.1016/j.amjmed.2017.06.026Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016;3:e379–87Li A, Garcia DA, Lyman GH, Carrier M. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res [Internet]. 2019;173:158–63. Available from: https://doi.org/10.1016/j.thromres.2018.02.144Gobierno Nacional de Colombia. Decreto 2423 del 31 de 2006 - actualizado 2019. 2019Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. The ISPOR CHEERS Task Force Report. CHEERS Checklist. Items to include when reporting economic evaluations of health interventions. 2019instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURRivaroxabánDalteparinaCáncerTromboembolismoFarmacoeconomíaCiencias médicas, Medicina610600RivaroxabánDalteparinCancerThromboembolismPharmacoeconomicsMedicinaEpidemiologíaCoste-efectividad del Rivaroxabán frente a Dalteparina para prevención de trombosis recurrente en el paciente con cáncerbachelorThesisTrabajo de gradoTrabajo de gradohttp://purl.org/coar/resource_type/c_7a1fORIGINALPuentes A Yate J Rivaroxaban - Dalteparina E45 20190820.pdfPuentes A Yate J Rivaroxaban - Dalteparina E45 20190820.pdfapplication/pdf1232708https://repository.urosario.edu.co/bitstreams/dfd0fa72-bd7b-4cad-b117-3050566ebf62/downloada97fbdbad94f62c7718919777d6b1656MD51LICENSElicense.txtlicense.txttext/plain1475https://repository.urosario.edu.co/bitstreams/8170550e-61f4-4c95-a91d-847e24ec0ac9/downloadfab9d9ed61d64f6ac005dee3306ae77eMD52CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8811https://repository.urosario.edu.co/bitstreams/6d5e9969-bce4-42ff-9585-d3eeafe1187b/download217700a34da79ed616c2feb68d4c5e06MD53TEXTPuentes A Yate J Rivaroxaban - Dalteparina E45 20190820.pdf.txtPuentes A Yate J Rivaroxaban - Dalteparina E45 20190820.pdf.txtExtracted texttext/plain188272https://repository.urosario.edu.co/bitstreams/2f81d35d-fcda-42b5-a725-6bed33060d05/download1ea926c602ab41562815469d2169ac97MD54THUMBNAILPuentes A Yate J Rivaroxaban - Dalteparina E45 20190820.pdf.jpgPuentes A Yate J Rivaroxaban - Dalteparina E45 20190820.pdf.jpgGenerated Thumbnailimage/jpeg2522https://repository.urosario.edu.co/bitstreams/8d7e89ba-84c2-4ed4-8917-fe22c948de98/download9083dba89e2f9c3a2db77e491d53ea72MD5510336/20367oai:repository.urosario.edu.co:10336/203672021-10-01 01:01:01.84807http://creativecommons.org/licenses/by-nc-nd/2.5/co/Atribución-NoComercial-SinDerivadas 2.5 Colombiahttps://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.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 |